Antibodies to GAD65 Epitopes at Diagnosis and Over the First 10 years of Clinical Type 1 Diabetes Mellitus
Antibodies to glutamate decarboxylase (GAD65Ab) may persist, and their titres even increase after the clinical onset of type 1 diabetes. To characterize this phenomenon in detail, we analysed sequentially antibodies to GAD65 epitope clusters in a radio‐binding assay in patients with type 1 diabetes....
Gespeichert in:
| Veröffentlicht in: | Scandinavian journal of immunology 2004-03, Vol.59 (3), p.334-340 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 340 |
|---|---|
| container_issue | 3 |
| container_start_page | 334 |
| container_title | Scandinavian journal of immunology |
| container_volume | 59 |
| creator | Ronkainen, M. S. Savola, K. Knip, M. |
| description | Antibodies to glutamate decarboxylase (GAD65Ab) may persist, and their titres even increase after the clinical onset of type 1 diabetes. To characterize this phenomenon in detail, we analysed sequentially antibodies to GAD65 epitope clusters in a radio‐binding assay in patients with type 1 diabetes. Serum samples were taken at diagnosis and 2, 5 and 10 years later from 50 young patients who had tested positive for GAD65Ab at least once during observation. The levels of GAD65Ab peaked in 21 patients after diagnosis. Antibodies to the middle region of GAD65 (GAD65‐M‐Ab, 88%) were more common at diagnosis than antibodies to the C‐terminal (GAD65‐C‐Ab, 68%, P |
| doi_str_mv | 10.1111/j.0300-9475.2004.01402.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71737762</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17980603</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4732-2317edc2e1c7e10ec1184b4abb243f19338f151e73622a49f7ae7557a91565a3</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhi0Eokvbv1BZHLglePwRJwcOq-0HRUU9sHfLyU6Ko2wc7AS6_x6HXYHEBXyxx37m1VgPIRRYDmm973ImGMsqqVXOGZM5A8l4_vyCrEAUKhOsFC_J6jd0Rt7E2DEGgmvxmpyBSk-qLFakWw-Tq_3OYaSTp3fr60LRm9FNfkw3dqLXzj4NPrpUDDv6-B0Dnb4ivXUhTmkeekAbIvUt3fRucI3t6fYwIoWlscYphXzGvnfTHC_Iq9b2ES9P-znZ3t5sNx-zh8e7-836IWukFjzjAjTuGo7QaASGDUApa2nrmkvRQiVE2YIC1KLg3Mqq1Ra1UtpWoAplxTl5d4wdg_82Y5zM3sUmzWAH9HM0GrTQuuD_BEFXJSuYSODbv8DOz2FIfzBQlVAUsoIElUeoCT7GgK0Zg9vbcDDAzCLNdGbxYRYfZpFmfkkzz6n16pQ_13vc_Wk8WUrAhyPww_V4-O9g8-XT_XISPwHnxqHo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198166491</pqid></control><display><type>article</type><title>Antibodies to GAD65 Epitopes at Diagnosis and Over the First 10 years of Clinical Type 1 Diabetes Mellitus</title><source>Wiley Free Content</source><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Ronkainen, M. S. ; Savola, K. ; Knip, M.</creator><creatorcontrib>Ronkainen, M. S. ; Savola, K. ; Knip, M.</creatorcontrib><description>Antibodies to glutamate decarboxylase (GAD65Ab) may persist, and their titres even increase after the clinical onset of type 1 diabetes. To characterize this phenomenon in detail, we analysed sequentially antibodies to GAD65 epitope clusters in a radio‐binding assay in patients with type 1 diabetes. Serum samples were taken at diagnosis and 2, 5 and 10 years later from 50 young patients who had tested positive for GAD65Ab at least once during observation. The levels of GAD65Ab peaked in 21 patients after diagnosis. Antibodies to the middle region of GAD65 (GAD65‐M‐Ab, 88%) were more common at diagnosis than antibodies to the C‐terminal (GAD65‐C‐Ab, 68%, P < 0.05) or N‐terminal region (4%, P < 0.001). Antibodies to middle and especially to C‐terminal epitopes decreased in those with decreasing levels of GAD65Ab (P < 0.001), whereas the frequencies of GAD65‐M‐Ab and GAD65‐C‐Ab remained quite stable among the subjects with increasing levels. Lower exogenous insulin dose and HbA1 levels and stronger humoral immune response to islet cells were observed in those with increasing levels of GAD65‐M‐Ab than in those with decreasing levels (P < 0.05). The present observation supports the view that the middle region of GAD65 comprises immunodominant epitopes. An enhanced humoral immune response to GAD65 after diagnosis is related to persistent immune reactivity to the middle and C‐terminal regions.</description><identifier>ISSN: 0300-9475</identifier><identifier>EISSN: 1365-3083</identifier><identifier>DOI: 10.1111/j.0300-9475.2004.01402.x</identifier><identifier>PMID: 15030586</identifier><language>eng</language><publisher>Oxford, UK; Malden , USA: Blackwell Science Ltd</publisher><subject>Adolescent ; Antibodies - immunology ; C-Reactive Protein - metabolism ; Child ; Child, Preschool ; Diabetes Mellitus, Type 1 - enzymology ; Diabetes Mellitus, Type 1 - immunology ; Female ; Glutamate Decarboxylase - immunology ; Glycated Hemoglobin A - metabolism ; HLA-DR Antigens - immunology ; Humans ; Immunodominant Epitopes - immunology ; Infant ; Insulin - administration & dosage ; Isoenzymes - immunology ; Longitudinal Studies ; Male</subject><ispartof>Scandinavian journal of immunology, 2004-03, Vol.59 (3), p.334-340</ispartof><rights>Copyright Blackwell Publishing Mar 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4732-2317edc2e1c7e10ec1184b4abb243f19338f151e73622a49f7ae7557a91565a3</citedby><cites>FETCH-LOGICAL-c4732-2317edc2e1c7e10ec1184b4abb243f19338f151e73622a49f7ae7557a91565a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.0300-9475.2004.01402.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.0300-9475.2004.01402.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15030586$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ronkainen, M. S.</creatorcontrib><creatorcontrib>Savola, K.</creatorcontrib><creatorcontrib>Knip, M.</creatorcontrib><title>Antibodies to GAD65 Epitopes at Diagnosis and Over the First 10 years of Clinical Type 1 Diabetes Mellitus</title><title>Scandinavian journal of immunology</title><addtitle>Scand J Immunol</addtitle><description>Antibodies to glutamate decarboxylase (GAD65Ab) may persist, and their titres even increase after the clinical onset of type 1 diabetes. To characterize this phenomenon in detail, we analysed sequentially antibodies to GAD65 epitope clusters in a radio‐binding assay in patients with type 1 diabetes. Serum samples were taken at diagnosis and 2, 5 and 10 years later from 50 young patients who had tested positive for GAD65Ab at least once during observation. The levels of GAD65Ab peaked in 21 patients after diagnosis. Antibodies to the middle region of GAD65 (GAD65‐M‐Ab, 88%) were more common at diagnosis than antibodies to the C‐terminal (GAD65‐C‐Ab, 68%, P < 0.05) or N‐terminal region (4%, P < 0.001). Antibodies to middle and especially to C‐terminal epitopes decreased in those with decreasing levels of GAD65Ab (P < 0.001), whereas the frequencies of GAD65‐M‐Ab and GAD65‐C‐Ab remained quite stable among the subjects with increasing levels. Lower exogenous insulin dose and HbA1 levels and stronger humoral immune response to islet cells were observed in those with increasing levels of GAD65‐M‐Ab than in those with decreasing levels (P < 0.05). The present observation supports the view that the middle region of GAD65 comprises immunodominant epitopes. An enhanced humoral immune response to GAD65 after diagnosis is related to persistent immune reactivity to the middle and C‐terminal regions.</description><subject>Adolescent</subject><subject>Antibodies - immunology</subject><subject>C-Reactive Protein - metabolism</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Diabetes Mellitus, Type 1 - enzymology</subject><subject>Diabetes Mellitus, Type 1 - immunology</subject><subject>Female</subject><subject>Glutamate Decarboxylase - immunology</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>HLA-DR Antigens - immunology</subject><subject>Humans</subject><subject>Immunodominant Epitopes - immunology</subject><subject>Infant</subject><subject>Insulin - administration & dosage</subject><subject>Isoenzymes - immunology</subject><subject>Longitudinal Studies</subject><subject>Male</subject><issn>0300-9475</issn><issn>1365-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1v1DAQhi0Eokvbv1BZHLglePwRJwcOq-0HRUU9sHfLyU6Ko2wc7AS6_x6HXYHEBXyxx37m1VgPIRRYDmm973ImGMsqqVXOGZM5A8l4_vyCrEAUKhOsFC_J6jd0Rt7E2DEGgmvxmpyBSk-qLFakWw-Tq_3OYaSTp3fr60LRm9FNfkw3dqLXzj4NPrpUDDv6-B0Dnb4ivXUhTmkeekAbIvUt3fRucI3t6fYwIoWlscYphXzGvnfTHC_Iq9b2ES9P-znZ3t5sNx-zh8e7-836IWukFjzjAjTuGo7QaASGDUApa2nrmkvRQiVE2YIC1KLg3Mqq1Ra1UtpWoAplxTl5d4wdg_82Y5zM3sUmzWAH9HM0GrTQuuD_BEFXJSuYSODbv8DOz2FIfzBQlVAUsoIElUeoCT7GgK0Zg9vbcDDAzCLNdGbxYRYfZpFmfkkzz6n16pQ_13vc_Wk8WUrAhyPww_V4-O9g8-XT_XISPwHnxqHo</recordid><startdate>200403</startdate><enddate>200403</enddate><creator>Ronkainen, M. S.</creator><creator>Savola, K.</creator><creator>Knip, M.</creator><general>Blackwell Science Ltd</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200403</creationdate><title>Antibodies to GAD65 Epitopes at Diagnosis and Over the First 10 years of Clinical Type 1 Diabetes Mellitus</title><author>Ronkainen, M. S. ; Savola, K. ; Knip, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4732-2317edc2e1c7e10ec1184b4abb243f19338f151e73622a49f7ae7557a91565a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adolescent</topic><topic>Antibodies - immunology</topic><topic>C-Reactive Protein - metabolism</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Diabetes Mellitus, Type 1 - enzymology</topic><topic>Diabetes Mellitus, Type 1 - immunology</topic><topic>Female</topic><topic>Glutamate Decarboxylase - immunology</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>HLA-DR Antigens - immunology</topic><topic>Humans</topic><topic>Immunodominant Epitopes - immunology</topic><topic>Infant</topic><topic>Insulin - administration & dosage</topic><topic>Isoenzymes - immunology</topic><topic>Longitudinal Studies</topic><topic>Male</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ronkainen, M. S.</creatorcontrib><creatorcontrib>Savola, K.</creatorcontrib><creatorcontrib>Knip, M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Scandinavian journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ronkainen, M. S.</au><au>Savola, K.</au><au>Knip, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibodies to GAD65 Epitopes at Diagnosis and Over the First 10 years of Clinical Type 1 Diabetes Mellitus</atitle><jtitle>Scandinavian journal of immunology</jtitle><addtitle>Scand J Immunol</addtitle><date>2004-03</date><risdate>2004</risdate><volume>59</volume><issue>3</issue><spage>334</spage><epage>340</epage><pages>334-340</pages><issn>0300-9475</issn><eissn>1365-3083</eissn><abstract>Antibodies to glutamate decarboxylase (GAD65Ab) may persist, and their titres even increase after the clinical onset of type 1 diabetes. To characterize this phenomenon in detail, we analysed sequentially antibodies to GAD65 epitope clusters in a radio‐binding assay in patients with type 1 diabetes. Serum samples were taken at diagnosis and 2, 5 and 10 years later from 50 young patients who had tested positive for GAD65Ab at least once during observation. The levels of GAD65Ab peaked in 21 patients after diagnosis. Antibodies to the middle region of GAD65 (GAD65‐M‐Ab, 88%) were more common at diagnosis than antibodies to the C‐terminal (GAD65‐C‐Ab, 68%, P < 0.05) or N‐terminal region (4%, P < 0.001). Antibodies to middle and especially to C‐terminal epitopes decreased in those with decreasing levels of GAD65Ab (P < 0.001), whereas the frequencies of GAD65‐M‐Ab and GAD65‐C‐Ab remained quite stable among the subjects with increasing levels. Lower exogenous insulin dose and HbA1 levels and stronger humoral immune response to islet cells were observed in those with increasing levels of GAD65‐M‐Ab than in those with decreasing levels (P < 0.05). The present observation supports the view that the middle region of GAD65 comprises immunodominant epitopes. An enhanced humoral immune response to GAD65 after diagnosis is related to persistent immune reactivity to the middle and C‐terminal regions.</abstract><cop>Oxford, UK; Malden , USA</cop><pub>Blackwell Science Ltd</pub><pmid>15030586</pmid><doi>10.1111/j.0300-9475.2004.01402.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-9475 |
| ispartof | Scandinavian journal of immunology, 2004-03, Vol.59 (3), p.334-340 |
| issn | 0300-9475 1365-3083 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71737762 |
| source | Wiley Free Content; MEDLINE; IngentaConnect Free/Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adolescent Antibodies - immunology C-Reactive Protein - metabolism Child Child, Preschool Diabetes Mellitus, Type 1 - enzymology Diabetes Mellitus, Type 1 - immunology Female Glutamate Decarboxylase - immunology Glycated Hemoglobin A - metabolism HLA-DR Antigens - immunology Humans Immunodominant Epitopes - immunology Infant Insulin - administration & dosage Isoenzymes - immunology Longitudinal Studies Male |
| title | Antibodies to GAD65 Epitopes at Diagnosis and Over the First 10 years of Clinical Type 1 Diabetes Mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T03%3A27%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibodies%20to%20GAD65%20Epitopes%20at%20Diagnosis%20and%20Over%20the%20First%2010%20years%20of%20Clinical%20Type%201%20Diabetes%20Mellitus&rft.jtitle=Scandinavian%20journal%20of%20immunology&rft.au=Ronkainen,%20M.%20S.&rft.date=2004-03&rft.volume=59&rft.issue=3&rft.spage=334&rft.epage=340&rft.pages=334-340&rft.issn=0300-9475&rft.eissn=1365-3083&rft_id=info:doi/10.1111/j.0300-9475.2004.01402.x&rft_dat=%3Cproquest_cross%3E17980603%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198166491&rft_id=info:pmid/15030586&rfr_iscdi=true |